|Year : 2004 | Volume
| Issue : 1 | Page : 20-24
Reversal of phenytoin-induced impairment of spontaneous alternation by piracetam in mice: Involvement of cholinergic system
M Shahid , KK Pillai , Divya Vohora
Department of Pharmacology, Faculty of Pharmacy, Jamia Hamdard, New Delhi - 110062,, India
Department of Pharmacology, Faculty of Pharmacy, Jamia Hamdard, New Delhi - 110062,, India
Objective: To study the effect of the combined treatment of phenytoin and piracetam on seizure control, cognitive and motor functions in mice.
Material and Methods: Increasing current electroshock seizure (ICES) test was used to evaluate the effect of the combination of phenytoin and piracetam on convulsions. Cognitive functions in mice were assessed by spontaneous alternation in behavior on a plus maze while motor functions were screened using rolling roller apparatus and by counting the number of arms entries on a plus maze. Brain acetylcholinesterase (AChE) activity was measured using the Ellman et al method.
Results: The study showed that piracetam when co-administered with phenytoin, significantly reversed phenytoin-induced reduction in spontaneous alternation without altering the efficacy of phenytoin against ICES in both acute and chronic studies. Further, it also reversed phenytoin-induced increase in AChE activity.
Conclusion: Piracetam alleviated the phenytoin–induced cognitive impairment without compromising its antiepileptic efficacy.
|How to cite this article:|
Shahid M, Pillai K K, Vohora D. Reversal of phenytoin-induced impairment of spontaneous alternation by piracetam in mice: Involvement of cholinergic system. Indian J Pharmacol 2004;36:20-4
|How to cite this URL:|
Shahid M, Pillai K K, Vohora D. Reversal of phenytoin-induced impairment of spontaneous alternation by piracetam in mice: Involvement of cholinergic system. Indian J Pharmacol [serial online] 2004 [cited 2020 Jan 22];36:20-4. Available from: http://www.ijp-online.com/text.asp?2004/36/1/20/6787
| » Introduction|| |
Phenytoin (PHT) is one of the low-cost and widely prescribed antiepileptic drugs (AED) known to cause cognitive impairment. Many studies have investigated the effect of PHT on learning, memory and psychomotor functions. Both acute and chronic administration of PHT has been shown to significantly impair learning and memory.,, For an optimum antiepileptic therapy, it is desirable to have complete seizure control without interfering cognitive effects. A combination of antiepileptic drugs (AEDs) with known nootropic agents appears to be a promising research area for desirable seizure control with minimal/no memory deficit. A better approach would be to use an agent that not only corrects the cognitive disturbances but also provides seizure protection. In this regard, one of the promising agents is piracetam (PIM).
PIM (2-oxo-1-pyrolidone acetamide)-a nootropic-has been shown to be an effective antimyoclonic agent.,, It has been shown to have a specific antiamnesic activity in many experimental paradigms.,, In addition, it has demonstrated a protective effect against pentylenetetrazol (PTZ) kindling-induced neuronal loss and learning deficit. However, it lacks anticonvulsant activity in the MES model. Convincing neuroprotective functions have also been shown experimentally., Thus it would be worthwhile to assess the use of PIM along with PHT on seizure and cognitive functions.
The central cholinergic system plays an important role in learning and memory.,, PHT is known to reduce hippocampal ACh concentration.,, In view of this we also studied the effect of this combination on the brain cholinergic system. Since the majority of AEDs including PHT are known to impair motor performance, the study also evaluated this combination on motor function.
| » Material and Methods|| |
Swiss albino mice of either sex (24-34 g), supplied by the Central Animal House Facility of Jamia Hamdard, New Delhi (Registration no. 173/CPCSEA) were used. All animals were housed in cages in groups of 10, at 23-300C with a natural light-dark cycle. They had free access to standard pellet diet (Amrut Laboratory rat and mice feed, Navmaharashtra Chakan oil mills Ltd., Pune) and tap water.
The study has been approved by the Ethics committee, CPCSEA (project no. 64, Nov. 2001). Ethical norms were strictly followed during all experimental procedures.
Drugs and dosing schedules
The following drugs were used: Phenytoin ('Dilantin' suspension, Parke Davis) was given p.o. in a volume of 10 ml/ kg body weight in doses of 8, 12 and 22 mg/kg body weight 2 h prior to each observation.
Piracetam ('Nootropil' syrup, UCB) was given p.o. in a volume of 10 ml/kg body weight in doses of 125, 250 and 500 mg/kg body weight 1 h prior to each experiment.
Control groups were given distilled water in a volume of 10 ml/kg body weight. Chronic studies were done for 21 days. All observations were made on day 21 after 2 h of phenytoin and 1 h of piracetam administration. In chronic studies, drugs were administered between 10-12 A.M.
Increasing Current Electroshock Seizures (ICES)
The ICES as proposed by Kitano et al and modified by Marwah et al was used to evaluate the anticonvulsant effect of the drugs. To start with a current of 2 mA electroshock to each mouse via ear electrodes as a single train of pulses (for 0.2 sec) was given with linearly increasing intensity of 2 mA / 2 sec using an electroconvulsometer (INCO, Ambala, India). The current at which tonic Hind Limb Extension (HLE) occurred was recorded as the seizure threshold current (STC). When no tonic HLE was observed by a current of 30 mA, electroshock was terminated.
Spontaneous Alteral Behavior (SAB) on a plus maze
Rodents have a natural tendency to alternate. An amnesic drug impairs this behavior and vice versa with nootropics. Hence, an increase in alternation implies improved cognition and vice versa. Cognitive functions were assessed using a plus maze proposed by Itoh et al and SAB was noted following the method of Ragozzino et al. The maze (height-50 cm) was constructed of wood, painted gray and contained a central platform (8 X 8 cm) from which radiated four symmetrical arms (23.5 X 8 cm) with 10 cm walls. After being placed in the central platform, mice were allowed to traverse the maze freely. The number and sequence of entries were recorded during an observation period of 6 min. An alternation was defined as entry into four different arms on overlapping quintuple sets. Five consecutive arms choices within the total set of arm choices make up a quintuple set, e.g. a quintuple set consisting of arms choices A, B, A, C, B was not considered an alternation. Using this procedure percentage alternation was calculated as follows:
Percentage alternation = X 100
Possible alternation = no. of arms entries -4
The number of arm entries was also recorded separately to determine the motor influence on the observed effects.
Rolling roller apparatus
This method as devised and proposed by Dunham et al was used to screen the neurological deficit caused by the drugs. The speed selector was set so that the roller made 5 revolutions/minute. The animals were placed on the roller for one minute as a testing time. A normal animal can maintain its equilibrium throughout the period. Neurological deficit was indicated by the inability of the animal to remain on the roller for a one-minute test period.
Estimation of brain acetylcholinesterase (AChE) activity
The whole brain AChE activity was measured using the Ellman et al method. This was measured on the basis of the formation of yellow color due to the reaction of thiocholine with dithiobisnitrobenzoate ions. The rate of formation of thiocholine from acetylcholine iodide in the presence of tissue cholinesterase was measured using a spectrophotometer. The sample was first treated with 5,5'-dithionitrobenzoic acid (DTNB) and the optical density(OD) of the yellow color compound formed during the reaction at 412 nm every minute for a period of three minutes was measured. Protein estimation was done using Folin's method. AChE activity was calculated using the following formula:
Where R= rate of enzyme activity in 'n' mole of acetylthiocholine iodide hydrolyzed / minute / mg protein
d O.D = Change in absorbance / minutes
E = Extinction coefficient = 13600 /M/cm
The data were expressed as mean+SEM. The normally distributed data were subjected to one-way ANOVA followed by Dunnett's test. Kruskal Wallis one-way ANOVA followed by multiple range test was used for the analysis of non-normally distributed data. P values <0.05 were considered significant.
| » Results|| |
Increasing current electroshock seizures (ICES)
Acute studies: PHT (22 mg/kg, p.o.) showed 100% protection against ICES as evidenced by a complete abolition of HLE. PHT (12 mg/kg, p.o.) produced 50% protection while a low dose of PHT (8 mg/kg, p.o.) afforded 0% protection [Table - 1].
PIM, at memory improving doses derived from [Table - 1] was found ineffective on ICES [Table - 1].
Spontaneous alternation behavior
The administration of PHT (12-22 mg/kg, p.o.), significantly reduced percentage alternation on plus maze, which accounts for the adverse effect on cognitive function. A lower dose (8 mg/kg, p.o.) did not elicit such an effect [Table - 1].
PIM (250-500 mg/kg, p.o.) showed significant elevation of percentage alternation while a dose of 125 mg/kg was ineffective [Table - 1].
Combined treatment with PHT (12 mg/kg, p.o.) and PIM (250 mg/kg) showed effects similar to the control group i.e. no deteriorating effect on memory without altering any effect on ICES [Table - 1].
PHT (12 mg/kg, p.o. X 21 days) caused a significant reduction in the percentage alternation i.e. markedly impaired memory. Combination of PIM (125 mg/kg, p.o. X 21 days) with PHT (125 mg/kg, p.o. X 21 days) reversed such an impairment [Table - 2].
Rolling roller apparatus: No dose of PHT and PIM in both acute and chronic studies, as well as in combination, produced any motor deficit.
Whole brain AChE activity
The whole brain AChE activity with PHT (8 mg/kg, p.o.) did not differ from the control. However, PHT (12 mg/kg, p.o.) demonstrated a significant rise in AChE activity as compared to control. PIM at a dose of 125 mg/kg, p.o. did not alter brain AChE activity significantly but at a dose of 250 mg/kg, p.o. lowered AChE levels significantly. A combination of PHT (12 mg/kg, p.o.) and PIM (250 mg/kg, p.o.) exhibited AChE levels similar to control [Table - 3].
| » Discussion|| |
The results of the present study show that PHT in doses 12-22 mg/kg, p.o., adversely affected the cognitive function in both acute and chronic studies. These doses were indeed found to be ED50 and ED100 against ICES. This result is in agreement with the previous studies of PHT on cognitive functions.,,
PIM, a well-known nootropic agent,, as well as an antimyoclonic agent,, exhibited significant nootropic effect on spontaneous alternation behavior, a model specific for measuring spatial memory in rodents. At the nootropic doses used, it was found to be ineffective against ICES thus consistent with the earlier reports on the MES model. Higher doses of PIM, however, were found to have significant antiepileptic effect against ICES (data not shown). The present study was based on the assumption that coadministration of PIM with clinically used AED might be useful in reducing some of the cognitive adverse effects of antiepileptic therapy. Our study showed that PIM, when coadministered with PHT, significantly reversed PHT-induced cognitive impairment without altering the efficacy of PHT against ICES. In the chronic study, PIM at lower dose of 125 mg/kg enhanced the percentage alternation but it was not statistically significant. This dose, however, could reverse the PHT-induced impairment of SAB. This is in agreement with another report where PIM was shown to prevent PTZ kindling-induced neuronal loss and learning deficits. To study the effect of motor influences on observed effects, the rolling roller apparatus was used but PIM alone, as well as in combination with PHT, did not exhibit any significant effect on motor functions. Further, the number of arm entries remained unaffected in SAB, thus ruling out the involvement of motor functions in the observed cognitive effects.
The precise mechanism by which PIM exerts its nootropic effect is not known. Multiple mechanisms have been suggested such as an enhancement of oxidative glycolysis, an effect on the Ca2+ channels and an effect on the cholinergic system. The latter is known to have an important role in the learning and memory processes. In our study, PHT, per se (12 mg/kg, p.o.) significantly elevated the 'brain AChE activity'. PIM (250 mg/kg, p.o.) on the other hand significantly lowered this activity indicating the counteracting action of the two drugs on the cholinergic system. The impairing effects of PHT on learning and memory have been attributed to alternations in the cholinergic system.,, It has been reported that PHT lowers brain ACh levels.,, Our results on AChE are thus consistent with these reports. It is worth noting that PHT at 8 mg/kg, p.o., did not show an impairment and did not affect AChE levels.
PIM is a member of the pyrrolidones group. Most of the pyrrolidones are known to influence cholinergic functions. ACh production and turnover are stimulated by most pyrrolidones but with varying actions at muscarinic and nicotinic receptors.,, In our study PIM reduced the AChE activity of the brain. But, more importantly, in this context, it is interesting to note that when coadministered with an effective dose of PHT, PIM significantly alleviated the PHT-induced sharp rise in total brain AChE level, indicating the counteracting action of PIM and PHT on the cholinergic system.
To conclude, PIM when coadministered with therapeutic doses of PHT, significantly alleviated the adverse effects of PHT on cognitive function without compromising its antiepileptic efficacy, the effect possibly mediated by an action on the cholinergic system. However, clinical studies are required to explore the full potential of PIM in correcting PHT-induced cognitive deficits and finding a place in the current AED therapy.
| » References|| |
|1.||Aldenkamp AD, Alpherts WCJ, Diepman L, Vantslot B, Overweg J, Vermenlen J. Cognitive side effects of phenytoin comapred with carbamazepine in patients with localization-related epilepsy. Epilepsy Res 1994;19:37-43. |
|2.||Sudha S, Madepalli K, Lakshmana, Pradhan N. Chronic phenytoin induced impairment of learning and memory with associated changes in brain acetylcholinesterase activity and monoamine levels. Pharmacol Biochem Behav 1995;52:119-24. |
|3.||Vohora D, Pal SN, Pillai KK. Protection from phenytoin-induced cognitive deficit by Bacopa monniera, a reputed Indian nootropic plant. J Ethnopharmacol 2000;71:383-90. [PUBMED] [FULLTEXT]|
|4.||Fedi M, Reutens D, Dubeau F, Andermann E, D'Agostina D, Andermann F. Long term efficacy and safety of piracetam in the treatment of progressive myoclonus epilepsy. Arch Neurol 2001;58:781-6. |
|5.||Brown P, Steiger MJ, Thompson PD. Effectiveness of piracetam in cortical myoclonus. Move Disorder 1993;9:63-8. |
|6.||Vleymen VB, Zandijcke VM. Piracetam in the treatment of myoclonus: an overview. Acta Neurol Belg 1996;96:270-80. |
|7.||Lenegre A, Chermat R, Avril I, Steru L, Porsolt RD. Specificity of piracetam's antiamnesic activity in three models of amnesia in the mouse. Pharmacol Biochem Behav 1988;29:625-9. [PUBMED] |
|8.||Verloes R, Scott AM, Gobert J, Wulfer E. Effects of nootropic drugs in scopolamine-induced amnesia model in mice. Psychopharmacol 1988;95:226-30. |
|9.||Christoffersen GRJ, Kemp A, Orlygsdottir G. Piracetam inhibit Pavlovian extinction and reversal learning in a spatial task for rats. Neuropharmacol 1998;37:815-25. |
|10.||Pohle W, Becker A, Grecksch G, Juhre A, Willenberg A. Piracetam prevents pentylenetetrazol kindling-induced neuronal loss and learning deficit. Seizure 1997;6:467-74. |
|11.||Hitzenberg G, Rameis H, Manigley C. Pharmacological properties of piracetam: rational for use in stroke patients. CNS Drugs 1998;9:19-27. |
|12.||Orgaogozo JM. Piracetam in the treatment of acute stroke. CNS drugs 1998;9:41-9. |
|13.||Biegon A. Greenberger V, Segal M. Quantitative histochemistry of brain acetylcholineesterase and learning in the aged rat. Neurobiol Aging 1986;7:215-7. |
|14.||Perry EK, Tomlinson BE, Blessed G, Bergman K, Gibson PH, Perry RH. Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia. Br Med J 1978;2:1457-9. |
|15.||Perry EK. Cholinergic component of cognitive impairment in dementia. In: Burns A, Levy R, editors. London: Dementia, Chapman and Hall; 1994. |
|16.||Agarwal SL, Bhargava V. Effect of drugs on brain acetylcholine level in rats. Indian J Med Res 1964;52:1179-82. [PUBMED] |
|17.||Domino EF, Olds ME. Effects of d-amphetamine, scopolamine, chlordiazepoxide and diphenylhydantoin on self stimulation and brain acetylcholine. Psychopharmacol 1972;23:1-16. [PUBMED] |
|18.||Kitano Y, Usui C, Takasuna K, Hirohashi M, Nomura M. Increasing current electroshock seizure test. A new method for assessment of anti-and proconvulsant activities of drugs in mice. J Phamacol Toxicol Methods 1996;35:25-9. |
|19.||Marwah R, Pal SN, Pillai KK. Effect of fluoxetine on increasing current electroshock seizures (ICES) in mice. Indian J Pharmacol 1999;31:350-3. |
|20.||Itoh J, Nabeshima J, Kameyama T. Utility of an elevated plus-maze for the evaluation of memory in mice: effects of nootropics, scopolamine and electroconvulsive shock. Psychopharmacol 1990;101:27-33. |
|21.||Ragozzino ME, Pal SN, Unick K, Stegani MR, Gold PE. Modulation of hippocampal acetylcholine release and spontaneous alternation scores by intrahippocampal glucose injection. J Neurobiol 1998;18:1595-601. |
|22.||Dunham NW, Miyo TS. A note on a simple apparatus for detecting neurological deficits in rats and mice. J Am Pharma Ass 1957;XLVI: 208-9. |
|23.||Ellman GL, Courtney KD, Valentino A Jr, Featherstone RM. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharmacol 1961;7:88-95. |
|24.||Shorvon S. Pyrrolidone derivatives. Lancet 2001;358:1885-92. [PUBMED] [FULLTEXT]|
|25.||Verbnyi YaI, Derzhiruk LP, Mogilevskii AYa. Piracetam induced changes in the functional activity of neurons as a possible mechanism for the effects of nootropic agents. Neurosci Behav Physio 1996;26:507-15. [PUBMED] |